Core Insights - Intuitive Surgical (ISRG) is focusing on cardiac surgery as a long-term growth opportunity for the da Vinci 5 platform following recent FDA regulatory approvals [2][3] - The company estimates an immediate opportunity for the da Vinci 5 system at approximately 160,000 annual cardiac procedures in cleared markets, compared to around 17,000 procedures performed globally using older da Vinci systems in 2025 [3][6] - The approach to the cardiac segment will be cautious, involving a gradual rollout supported by specialized training and collaboration with surgical societies [4][6] Company Initiatives - Intuitive Surgical is developing cardiac-specific instrumentation and technologies, including Force Feedback instruments, to enhance the capabilities of the da Vinci 5 system [5][6] - The company is refining digital tools to support procedure planning and intraoperative guidance, aiming to facilitate broader surgeon adoption of robotic cardiac procedures [5][6] - The initiatives suggest that while cardiac surgery may not be a near-term revenue driver, it could significantly expand ISRG's total addressable market (TAM) over the long term [6] Peer Updates - Zimmer Biomet (ZBH) is positioning its ROSA robotic platform for long-term growth through expanding clinical indications and technology integration, with strong sales and increasing adoption in robotic-assisted orthopedics [7][8] - Stryker (SYK) is accelerating the clinical scope of its Mako robotic system, with record installations and expanding indications into advanced primary hips, revision hips, and spine procedures [9][10] Financial Performance - ISRG shares have increased by 12.9% over the past six months, outperforming the industry, which saw a decline of 3.2% [12] - The forward price-to-earnings ratio for Intuitive Surgical is 47.74, above the industry average but lower than its five-year median of 70.97 [13] - The Zacks Consensus Estimate for ISRG's 2026 earnings indicates a 12.7% increase compared to the previous year [14]
ISRG's da Vinci Gains FDA Nod for Cardiac Surgery: TAM Growth Ahead?